{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:05:44Z","timestamp":1792659944995,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":6215,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2003,1]]},"DOI":"10.1093\/annonc\/mdg029","type":"journal-article","created":{"date-parts":[[2002,12,17]],"date-time":"2002-12-17T22:16:46Z","timestamp":1040163406000},"page":"97-104","source":"Crossref","is-referenced-by-count":135,"title":["Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial"],"prefix":"10.1016","volume":"14","author":[{"given":"W.","family":"Scheithauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Sch\u00fcll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ulrich-Pur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Raderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Kwasny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Depisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.V.","family":"Kornek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdg029_bb0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3322\/canjclin.48.1.6","article-title":"Cancer statistics, 1998","volume":"48","author":"Landis","year":"1998","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mdg029_bb0015","first-page":"220","article-title":"Chemotherapy of adenocarcinoma of the pancreas","volume":"23","author":"Schnall","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0020","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0025","first-page":"273a","article-title":"Randomized phase II trial of dose intense gemcitabine by standard infusion versus fixed dose rate in metastatic pancreatic adenocarcinoma","volume":"18","author":"Temporo","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0030","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF00194529","article-title":"Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team","volume":"14","author":"Von Hoff","year":"1996","journal-title":"Invest New Drugs"},{"issue":"Suppl 11","key":"10.1093\/annonc\/mdg029_bb0035","first-page":"47","article-title":"Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors","volume":"22","author":"Csoka","year":"1995","journal-title":"Semin Oncol"},{"issue":"Suppl 11","key":"10.1093\/annonc\/mdg029_bb0040","first-page":"1","article-title":"Gemcitabine: status of preclinical studies and perspectives for future clinical applications of this novel nucleoside analog","volume":"22","author":"Godefridus","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0045","first-page":"93","article-title":"In vitro evaluierung potentiell effektiver gemcitabine-kombinationstherapien beim exokrinen pankreaskarzinom","volume":"26","author":"Kreil","year":"1999","journal-title":"Acta Med Austriaca"},{"key":"10.1093\/annonc\/mdg029_bb0050","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1200\/JCO.1994.12.8.1535","article-title":"Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study","volume":"12","author":"Abratt","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0055","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1200\/JCO.1994.12.9.1821","article-title":"Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study","volume":"12","author":"Anderson","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0060","article-title":"Gemcitabine in non-small-cell lung cancer: the Japanese experience","author":"Fukuoka","year":"1994","journal-title":"Presented at the Seventh World Conference on Lung Cancer, Symposium \u2018Efficacy, Symptomatology and Costs as Decision Points in Lung Cancer Treatment: Investigational Experience with Gemcitabine\u2019"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdg029_bb0065","first-page":"120","article-title":"Results of phase II studies of gemcitabine in patients with non-small-cell lung cancer in Japan","volume":"11","author":"Nakai","year":"1994","journal-title":"Lung Cancer"},{"issue":"Suppl 6","key":"10.1093\/annonc\/mdg029_bb0070","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1016\/0959-8049(93)91505-F","article-title":"Confirmatory activity of gemcitabine in non-small-cell lung cancer","volume":"29A","author":"LeChevalier","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdg029_bb0075","first-page":"383","article-title":"Phase I study of gemcitabine given weekly as short infusion","volume":"14","author":"Kassem","year":"1995","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0080","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.1997.15.1.310","article-title":"Maximum-tolerated dose defined for single agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer","volume":"15","author":"Fossella","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0085","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/1097-0142(20000601)88:11<2505::AID-CNCR11>3.0.CO;2-E","article-title":"A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma","volume":"88","author":"Ulrich-Pur","year":"2000","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdg029_bb0090","first-page":"274a","article-title":"Gemcitabine and cisplatin in the treatment of advanced and metastatic pancreatic cancer: final results of a phase II study","volume":"18","author":"Heinemann","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0095","first-page":"274a","article-title":"Phase II study of gemcitabine and cisplatin in advanced or metastatic pancreatic cancer","volume":"18","author":"Philip","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0100","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1023\/A:1008393010472","article-title":"A combination of a fixed dose rate of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)","volume":"11","author":"Cascinu","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0105","first-page":"265a","article-title":"A phase I\u2013II study of gemcitabine (GEM) plus continuous infusion (CI) 5-fluorouracil (5-FU) in patients with advanced pancreatic cancer (APC)","volume":"17","author":"Cortes-Funes","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0110","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1023\/A:1008364018881","article-title":"A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with advanced pancreatic cancer","volume":"11","author":"Oettle","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0115","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1023\/A:1011139808426","article-title":"Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM)","volume":"12","author":"Louvet","year":"2001","journal-title":"Ann Oncol"},{"issue":"Suppl 10","key":"10.1093\/annonc\/mdg029_bb0120","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0093-7754(01)80008-7","article-title":"Phase II study of gemcitabine, 5-fluorouracil, and leucovorin in patients with pancreatic cancer","volume":"28","author":"Marantz","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0125","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/sj.bjc.6690600","article-title":"Phase II trial of gemcitabine, epirubicin, and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma","volume":"80","author":"Scheithauer","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdg029_bb0130","first-page":"288a","article-title":"Gemcitabine (G) and taxotere (T) in patients with unresectable pancreatic carcinoma","volume":"18","author":"Jacobs","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0135","first-page":"313a","article-title":"Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic cancer","volume":"19","author":"Clark","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0140","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000058527","article-title":"Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas","volume":"60","author":"Sherman","year":"2001","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdg029_bb0145","first-page":"154a","article-title":"Pancreatic cancer: biweekly gemcitabine\/docetaxel chemotherapy","volume":"20","author":"Shepard","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0150","first-page":"131b","article-title":"Docetaxel (D) with gemcitabine (GEM) in metastatic pancreatic cancer","volume":"20","author":"Gonzalez Cao","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0155","first-page":"157a","article-title":"Multicenter phase II study of weekly docetaxel and gemcitabine for the treatment of patients (pts) with advanced or recurrent pancreatic cancer","volume":"20","author":"Ridwelski","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0160","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1023\/A:1008310106171","article-title":"Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for pancreatic cancer","volume":"12","author":"Stathopoulos","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0165","first-page":"263a","article-title":"Multicenter phase II trial of first-line irinotecan and gemcitabine (Irinogem) in patients with locally advanced or metastatic pancreatic cancer (PC)","volume":"19","author":"Lima","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0170","first-page":"127a","article-title":"Gemcitabine-oxaliplatin (GEMOX) combination in advanced pancreatic carcinoma (APC): a Gercor multicenter phase II study","volume":"20","author":"Louvet","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0175","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1200\/JCO.2001.19.10.2679","article-title":"Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma","volume":"19","author":"Reni","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0180","first-page":"60","article-title":"Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer","volume":"20","author":"Cartwright","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0185","first-page":"2811","article-title":"Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2-deoxyuridine in HT-29 colon cancer cells","volume":"4","author":"Ren","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdg029_bb0190","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1200\/JCO.20.2.582","article-title":"Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer","volume":"20","author":"Schilsky","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0195","first-page":"267a","article-title":"Combining gemcitabine (GEM) and capecitabine (CAP) in advanced pancreatic cancer. Results of a phase I trial","volume":"19","author":"Herrmann","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl 6","key":"10.1093\/annonc\/mdg029_bb0200","first-page":"S135","article-title":"Gemcitabine (GEM) and capecitabine (CAP) for advanced pancreatic cancer. A phase I\/II trial","volume":"37","author":"Hess","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdg029_bb0205","first-page":"141b","article-title":"Gemcitabine (GEM) and capecitabine (CPC) in advanced pancreatic cancer (APC) and solid tumors. A single institution experience","volume":"20","author":"Campos","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0210","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdg029_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two stage design for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trial"},{"key":"10.1093\/annonc\/mdg029_bb0220","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2307\/3001616","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"key":"10.1093\/annonc\/mdg029_bb0225","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non-parametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1093\/annonc\/mdg029_bb0230","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1200\/JCO.2000.18.6.1337","article-title":"Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study","volume":"18","author":"Van Cutsem","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0235","first-page":"33a","article-title":"A phase III study of gemcitabine in combination with 5-FU versus gemcitabine alone in patients with advanced pancreatic adenocarcinoma (E2297): an Eastern Cooperative Oncology Group (ECOG) trial","volume":"20","author":"Berlin","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg029_bb0240","first-page":"154a","article-title":"Gemcitabine (GEM) alone or in combination with 5-FU continuous infusion (CI) in the treatment of advanced pancreatic cancer (APC): a GOIRC randomized phase II trial","volume":"20","author":"DiCostanzo","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl 9","key":"10.1093\/annonc\/mdg029_bb0245","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/sonc.2002.34269","article-title":"Present and future treatment of pancreatic cancer","volume":"29","author":"Heinemann","year":"2002","journal-title":"Semin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419639190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419639190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/14\/1\/97\/303075\/mdg029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T02:10:31Z","timestamp":1582251031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419639190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["S0923753419639190"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdg029","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2003,1]]}}}